Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy. Wang S, Hao X, Dai L, Lou N, et al. Lung Cancer 2024;189:107503.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang S, Hao X, Dai L, Lou N, et al. Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy. Lung Cancer 2024;189:107503.
PMID: 38359741